Microsoft Word - GILEAD BRIEFING - Ledipasvir - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2016-07-02 14:50:25 Health Medicine Breakthrough therapy Specialty drugs Gilead Sciences Healthcare-associated infections Cyclopropanes Sofosbuvir Ledipasvir National Institute for Health and Care Excellence Hepatitis National Health Service		Microsoft Word - GILEAD BRIEFING Add to Reading List Source URL: www.ukts.org Download Document from Source Website File Size: 102,77 KB Share Document on Facebook

	1978 Non-adherence is the most important risk factor for ledipasvir/sofosbuvir HCV treatment failure in the real world. Dost Sarpel1, Isaac Wasserman2, Alyssa L. Trochtenberg2, Kian Bichoupan1, David P. Del Bello1, Ponni DocID: 1t14c - View Document
	présenteit - mediA - phA rmA DocID: 1riP0 - View Document
	Microsoft Word - GILEAD BRIEFING DocID: 1r2Vm - View Document
	Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases DocID: 1qOAQ - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl DocID: 1qqPd - View Document